Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Is Intensifying Loco-Regional Treatment in the Early Course of De Novo Stage IV Breast Cancer Reasonable?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Soran A, Ozbas S. Surgery for the primary tumor in patients with de novo stage IV breast cancer. In: Aydiner A, İğci A, Soran A, eds. Breast disease, management, and therapies, Volume 2. Springer, Switzerland; 2016:455–64.

    Google Scholar 

  2. Bishop AJ, Ensor J, Moulder SL, et al. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015;121(24):4324–32. https://doi.org/10.1002/cncr.29681. Epub 2015 Sep 8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wong Y, Raghavendra AS, Hatzis C, et al. Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2)-positive breast cancers treated with HER2-targeted therapy. Oncologist. 2018. pii: theoncologist.2018-0213. https://doi.org/10.1634/theoncologist.2018-0213. [Epub ahead of print].

  4. Soran A, Ozmen V, Ozbas S. randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–9. https://doi.org/10.1245/s10434-018-6494-6. Epub 2018 May 17. PMID:29777404.

    Article  PubMed  Google Scholar 

  5. Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer (SUBMIT) https://clinicaltrials.gov/ct2/show/NCT01392586.

  6. Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer (POSYTIVE) https://clinicaltrials.gov/ct2/show/NCT01015625.

  7. Standard of care therapy with or without stereotactic radiosurgery and/or surgery in treating patients with limited metastatic breast cancer. https://clinicaltrials.gov/ct2/show/NCT02364557.

  8. Early surgery or standard palliative therapy in treating patients with stage IV breast cancer. https://clinicaltrials.gov/ct2/show/NCT01242800.

  9. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006333&type=summary&language=E.

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, PA, USA

    Atilla Soran MD, MPH

Authors
  1. Atilla Soran MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atilla Soran MD, MPH.

Ethics declarations

Disclosure

The author has no conflicts of interest to disclose.

Additional information

ASO Author Reflections is a brief invited commentary on the article, “Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.” Ann Surg Oncol. 2018;25:3141–9.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soran, A. ASO Author Reflections: Is Intensifying Loco-Regional Treatment in the Early Course of De Novo Stage IV Breast Cancer Reasonable?. Ann Surg Oncol 25 (Suppl 3), 663–664 (2018). https://doi.org/10.1245/s10434-018-6924-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6924-5

Keywords

Search

Navigation